Citral
CAS 141-27-5
Citral (CAS 141-27-5) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 29034.35 nM | 4 | - |
| - | IC50 | 28000 nM | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPV2 Trpv2 |
Inhibition | - | 18461159 |
| TRPV3 Trpv3 |
Activation | 3.03 pKd | 18461159 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CITRAL | 1362890 | SU | MTHSPL |
| citral | 1362890 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Citral used for in pharmaceutical contexts?
Citral (CAS 141-27-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Citral?
Citral has 0 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cataract, Glaucoma, Pancreaticoduodenectomy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Citral also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Geranial with EU status "restricted".
What clinical phase is Citral in?
No phase 1-4 clinical development badge is rendered for Citral because the matched compound identifier rows do not contain a max-phase value.